Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079612 · ClinicalTrials.gov registry record · Phase 2
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 501
- Enrollment target
NCT00079612: Completed Phase 2 study, sponsored by Bayer.
NCT00079612 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 501 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (277% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00079612, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 501 participants
- Enrollment target
Study Summary
The purpose of the study is to: * Find out if BAY 43-9006 prevents the growth of tumors * For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. * Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. * Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
Interventions
- DRUG Placebo
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00079612 record still lists
NCT00079612 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (277% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00079612 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00079612 about?
NCT00079612 is a clinical study titled "Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer". The purpose of the study is to: * Find out if BAY 43-9006 prevents the growth of tumors * For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. * Find out how long the e...
What is the current status of trial NCT00079612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 501 participants. The study started on 2002-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00079612?
The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00079612?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00079612's enrollment target sits among peer trials
501 70th of 2000 higher than 1,931 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia